Today, Taysha Gene Therapies announced that a 2nd adult patient has been dosed with TSHA-102 in their REVEAL Phase 1/2 trial of the investigational gene therapy in Canada. They expect to dose the 3rd adult patient and complete enrollment in this low-dose cohort by the end of this year, and plan to dose the first pediatric patient in the U.S. trial in the first quarter of 2024. To read the full press release, click here.
IRSF is with you every step of the way. For more information on the first adult patient dosed and future plans to study the gene therapy TSHA-102, click here. Questions? Email us at [email protected].